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1216Objective: Aberrant glycosylation has been implicated in various types of cancers. Cancerous cells with altered
glycosylation of their surface proteins shed such proteins into the circulating fluids. Glycomic profiling of such
fluids shows the altered glycosylation. We performed glycomic profiling of serum from patients with no known
disease, Barrett’s without dysplasia, with high-grade dysplasia, and with esophageal adenocarcinoma in an at-
tempt to delineate distinct differences in glycosylation among these groups.
Methods: Serum samples from patients with Barrett’s metaplasia (N ¼ 5), high-grade dysplasia (N ¼ 11), and
esophageal adenocarcinoma (N ¼ 50) were collected; samples from 18 healthy volunteers were used as control.
Serum N-glycans were enzymatically released and then applied to both C18 Sep-Pak (Waters, Milford, MA) car-
tridges and activated charcoal cartridges. N-glycans were permethylated and then spotted directly onto a matrix-
assisted laser desorption ionization plate. Mass spectra were acquired using the Applied Biosystems 4800
MALDI TOF/TOF Analyzer (Applied Biosystems Inc, Framingham, Mass). The obtained matrix-assisted laser
desorption ionization-mass spectrometry data were processed using DataExplorer files (Applied Biosystems Inc)
listing m/z values and intensities.
Results: The intensities of 98 glycans were significantly different among the 3 groups; 26 of these corresponded
to known glycan structures. Pairwise comparisons showed that 8 glycans were significantly different in all 3 pair-
wise comparisons.
Conclusion: We demonstrated that comparative glycomic profiling of esophageal adenocarcinoma reveals
a subset of glycans that can be selected as candidate biomarkers. These markers can differentiate normal from
high-grade dysplasia, normal from esophageal adenocarcinoma, and high-grade dysplasia from esophageal
adenocarcinoma. Further validation will be necessary to determine the clinical utility of these glycan biomarkers.
(J Thorac Cardiovasc Surg 2010;139:1216-23)Esophageal adenocarcinomas are thought to develop from
a premalignant lesion of the esophagus, referred to as Bar-
rett’s esophagus (BE). It is widely held that BE that eventu-
ally progresses to adenocarcinoma does so by a gradual
progression at the cellular level from a normal squamous
cell to the metaplastic columnar cell that is synonymous
with BE. However, the molecular mechanisms by which
such progression occurs and which patients with BE are at
greatest risk for this progression have yet to be elucidated.
A better understanding of the pathophysiology of Barrett’s
adenocarcinoma may help to identify those patients at in-
creased risk for malignant transformation. The identification
of novel biomarkers involved in the progression and ulti-
mate malignant transformation has the potential to result in
an earlier diagnosis and to improve the prognosis of patients
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The Journal of Thoracic and Cardiovascular SurAberrant glycosylation has been implicated in several
types of cancer.1-3 Molecular changes in glycosylation also
may be associated with the signaling pathways responsible
for the malignant transformation of cells.4 Because cancer
cells with altered glycosylation of their surface proteins
eventually shed such proteins into the circulating fluids, gly-
comic profiling of such fluids may reveal the altered glyco-
sylation. Glycomic profiling has been used to show glycan
alterations of several cancers, including breast,5 ovarian,6
prostate,7 and hepatocellular8 carcinomas. We hypothesized
that analysis of esophageal adenocarcinoma and its precur-
sors would show altered glycosylation and identify candidate
glycans that can differentiate or distinguish adenocarcinoma
from its precursors. These altered glycans may then serve as
potential biomarkers of esophageal adenocarcinoma and in-
dicate proteins involved in disease progression. We per-
formed comparative glycomic profiling of serum obtained
from patients with no known disease, patients with BE with-
out dysplasia, patients with BE and high-grade dysplasia
(HGD), and patients with esophageal adenocarcinoma in
an attempt to identify these altered glycans.MATERIALS AND METHODS
Collection of Serum Samples
All work was conducted under an Indiana University Purdue University
institutional review board-approved protocol. All subjects included in thegery c May 2010
Abbreviations and Acronyms
BE ¼ Barrett’s esophagus
HGD ¼ high-grade dysplasia
MALDI ¼ matrix-assisted laser desorption
ionization
MS ¼ mass spectrometry
ROC ¼ receiver operating characteristic
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Whole blood samples were collected from patients with histologically docu-
mented BE (n¼ 5), BE with HGD (n¼ 11), and adenocarcinoma (n¼ 50).
Blood samples from 18 healthy volunteers served as control. Each blood
sample was allowed to clot for 45 minutes and then centrifuged at 2000
rpm for 10 minutes. The serum was aspirated, placed in a separate vial,
and stored at80C until use.
Release of N-Glycans From Glycoproteins
After thawing, a 10-mL aliquot of serum was lyophilized and then re-
suspended in 100 mL of 25 mmol/L ammonium bicarbonate. N-glycans
were then enzymatically released using PNGase F according to our
previously published procedure.9 A 5 mU aliquot of PNGase F was
added to the reaction mixture and incubated overnight (18–22 hours)
at 37C.
Solid-Phase Extraction of Enzymatically Released
N-Glycans
The volume of enzymatically released glycans was adjusted to 1 mL by
adding deionized water. Samples were then applied to both C18 Sep-Pak
cartridges (Waters, Milford, Mass) and activated charcoal cartridges (Har-
vard Apparatus, Holliston, Mass). The reaction mixture was first applied
to the C18 Sep-Pak cartridge that had been preconditioned with ethanol
and deionized water according to the manufacturer’s recommendation.
The reaction mixture was circulated through the C18 Sep-Pak cartridge 5
times before washing with water. Peptides and O-linked glycopeptides
were retained on the C18 Sep-Pak cartridge, and the released glycans
were collected as eluents. Next, the C18 Sep-Pak cartridge was washed
with 1mL of deionized water. The combined eluents containing the released
N-glycans were then passed over activated charcoal microcolumns. The col-
umns were preconditioned with 1 mL of acetonitrile and 1 mL of 0.1% tri-
fluroacetic acid aqueous solution, as recommended by the manufacturer.
After applying the sample, the microcolumn was washed with 1 mL of
0.1% trifluroacetic acid aqueous solution. The samples were then eluted
with a 1-mL aliquot of 50% acetonitrile aqueous solution containing
0.1% trifluroacetic acid. Finally, the purified glycans were evaporated to
dryness using the vacuum CentriVap Concentrator (Labconco Corporation,
Kansas City, Mo) before solid-phase permethylation.
Solid-Phase Permethylation
Permethylation of enzymatically released and solid-phase purified
N-glycans was accomplished using our recently published solid-phase per-
methylation technique.10,11 This permethylation procedure has been shown
to minimize oxidative degradation and peeling reactions and to avoid the
need for excessive clean-up. Samples were infused through the reactor at
a slow flow rate of 2 mL/min, as previously described.10,11 The reactor
was then washed with 230 mL acetonitrile (flow rate: 5 mL/min). All
eluents were combined, and the permethylated N-glycans were finally
extracted using 200 mL chloroform and washed 3 times with 200 mL of
water before drying.The Journal of Thoracic and CarMatrix-Assisted Laser Desorption Ionization/Time of
Flight Mass Spectrometry Instrumentation
Permethylated glycans were resuspended in 2 mL of (50:50) methanol:-
water solution. A 0.5-mL aliquot of the sample was then spotted directly on
the matrix-assisted laser desorption ionization (MALDI) plate and mixed
with the equal volume of 2,5 dihydroxybenzoic acid-matrix prepared by
suspending 10 mg of 2,5 dihydroxybenzoic acid in 1 mL of (50:50) water:-
methanol solution containing 1 mmol/L sodium acetate. The MALDI plate
was then dried under vacuum to ensure uniform crystallization. Mass spec-
tra were acquired using the Applied Biosystems 4800 MALDI TOF/TOF
Analyzer (Applied Biosystems Inc, Framingham, Mass). This instrument
is equipped with a neodymium-doped yttrium aluminium garnet laser
with 355-nm wavelength. MALDI spectra were recorded solely in the
positive-ion mode, because permethylation eliminates the negative charge
normally associated with sialylated glycans.
Data Evaluation
MALDI mass spectrometry (MS) data were processed using Data-
Explorer 4.0 (Applied Biosystems Inc) to generate ASCII files listing
mass/charge (m/z) values and intensities. An in-house developed software
tool (PeakCalc 2.0) was then used to extract the intensities of N-glycans.
Principal component analysis was performed using MarkerView (Applied
Biosystems Inc), allowing the visualization of multivariate information. Su-
pervised principal component analysis methods were used, with a prior
knowledge of the sample groups as healthy versus diseased. MS data
were weighted using the base-e logarithm of the peak intensities. The
peak intensities were also scaled using the Pareto option, wherein each value
is subtracted by the average and divided by the square root of the standard
deviation. This option is suitable for MS data because it prevents intense
peaks from completely dominating the principal component analysis pro-
cess, thus allowing any peak with good signal-to-noise ratio to contribute.
Receiver operating characteristic (ROC) curve analysis with AccuROC
2.5 software for Windows (Accumetric Corporation, Montreal, Quebec,
Canada) was used to assess the sensitivity and selectivity of the potential di-
agnostic variables.
RESULTS
Table 1 shows the clinical stage of the 50 patients with
esophageal adenocarcinoma; none of the patients received
any therapy before serum collection. The intensity values
of 421 features were collected from 18 control subjects, 5 pa-
tients with BE, 11 patients with HGD, and 50 patients with
esophageal adenocarcinoma. Because the primary goal was
to compare these groups in terms of the relative intensity
values for each structure, and the number of BE samples
was limited (N ¼ 5), the BE and HGD groups were
combined. It is widely accepted that the total intensity of
each individual varies; thus, relative intensity is used for
comparison throughout the analysis described as follows.
Exploratory data analyses indicated that the relative inten-
sity of the original data violated the normality and constant
variance assumptions. After logarithm transformation of the
relative intensity, normality was improved but still not
achieved. As a result, a nonparametric method, the Krus-
kal–Wallis test,12 was used to test the equality of the me-
dians. Because of the large number of tests, the Bonferroni
method was used to correct for multiple comparisons with
an overall type I error rate controlled at 0.05. The statistical
significance of each glycan was determined by comparingdiovascular Surgery c Volume 139, Number 5 1217
TABLE 1. Clinical stage of 50patientswith esophageal adenocarcinoma
Clinical stage No. of specimens
T1N0 6
T2N0 5
T3N0 6
T2N1 1
T3N1 14
T4N1 1
T2-3Nx 2
M1a 7
M1b 5
Unknown 3
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If statistical significance was reached, comparisons of the
glycan intensities between each pair of the 2 groups were
performed using the Wilcoxon rank-sum test.13 All statisti-
cal analyses were carried out using R 2.5.0 and MATLAB
version 7.4 (The MathWorks Inc, Natick, Mass).
Results from the Kruskal–Wallis test showed that the rel-
ative intensities of 98 features were significantly different
among the 3 groups; of these, 26 glycans corresponded to
known glycan structures. Further pairwise comparisons us-
ing the Wilcoxon rank-sum test showed that only 8 glycans
with known structures were significantly different in all 3
pairwise comparisons, that is, comparisons between esoph-FIGURE 1. Plot of scores of principle components 1 and 2
1218 The Journal of Thoracic and Cardiovascular Surageal adenocarcinoma and control, between esophageal ad-
enocarcinoma and BE þ HGD, and between control and
BE þ HGD. The other 18 glycans with known structures
reached statistical significance in 2 of the 3 comparisons.
On the basis of these results, a subset of glycans were se-
lected as candidate biomarkers to differentiate all 3 groups
or to differentiate 1 group from the other 2 groups.
Figure 1 demonstrates the plot of the scores of principal
components 1 and 2 for all 4 groups. To a varying degree,
the 4 sets of samples received distinguishable first principal
component scores. Consequently, the 4 sets clustered in
a manner representative of the glycomic profile differences
for the 4 groups. However, samples from patients with BE
were distinguishable from samples from patients with
HGD only in the second principle component, suggesting
limited differences between them. We also examined the
changes in relative intensities of fucosylated (linkage of fu-
cose to polypeptides) and sialylated (linkage of sialic acid to
polypeptides) structures, because this is another means to
monitor changes in glycosylation patterns. Figure 2 shows
the results of this analysis. There was a statistically signifi-
cant (P< .005) decrease in total fucosylation of N-glycans
between controls and adenocarcinoma samples. A decrease
was also observed for the BE and HGD samples, although
this did not reach statistical significance. Unlike fucosyla-
tion, no significant change in sialylated N-glycans was de-
tected among the 4 groups.for all 4 groups analyzed. HGD, High-grade dysplasia.
gery c May 2010
FIGURE 2. Results of analysis of relative intensities of fucosylated (A) and sialylated (B) glycans. HGD, High-grade dysplasia.
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known N-glycans observed in the MALDI-MS were further
evaluated using 2 independent statistical approaches: Wil-
coxon rank-sum and ROC curve analyses. The relative in-
tensities of 16 N-glycan structures were statistically
different between control patients and patients with esopha-
geal adenocarcinoma, as suggested by Wilcoxon rank-sum
test P values. These data are summarized in Figure 3. Ac-
cording to ROC analysis area under the curve values, 3 of
these structures predict esophageal adenocarcinoma with
high accuracy, whereas the other structures predict adeno-
carcinoma with moderate accuracy. The relative intensities
of 14 N-glycans were lower in patients with adenocarci-
noma, whereas the relative intensities of 2 structures were
higher. Dot-plots representing the relative intensities ob-
served for some of the structures listed in Figure 3 are illus-
trated in Figure 4. The relative intensities of 16 N-glycan
structures were statistically different between controls and
those with HGD by Wilcoxon rank-sum test P values. Ac-
cording to ROC analysis area under the curve values, all
of the structures predict HGD with only moderate accuracy.
The relative intensities of 15 N-glycan structures were statis-
tically different between adenocarcinoma and HGD by Wil-
coxon rank-sum test P values. According to ROC area under
the curve values, all of these structures predict HGD with
only moderate accuracy. Figure 5 demonstrates the dot-
plot analysis of the individual clinical stage of the esopha-
geal adenocarcinoma specimens.
DISCUSSION
Altered glycosylation has been demonstrated in a variety of
cancers, including those of the breast, prostate, and liver.1-3The Journal of Thoracic and CarWe have demonstrated altered glycosylation in esophageal
adenocarcinoma and its known precursor lesions. It is well
established that post-translational modification of proteins
(eg, glycosylation) is a common means by which cell signal-
ing is accomplished. With respect to glycoproteins, such
modifications/alterations may provide insight into the mech-
anism(s) of altered glycosylation and indicate the structural
changes of glycoproteins during carcinogenesis, thereby
identifying potential biomarkers of disease development or
progression. By using principle component analysis, we dem-
onstrated a distinct clustering among the 4 sample groups an-
alyzed, with a significant difference between controls and
adenocarcinoma. We also noted an intermediate difference
between controls and those with BE/HGD, suggesting that al-
tered glycosylation may indicate disease progression. Such
findings support the potential to use serum glycomic profiling
to diagnose each disease state and monitor the progression of
disease from BE/HGD to adenocarcinoma. Furthermore, al-
tered glycosylation appears to differ in each stage of adeno-
carcinoma (Figure 5), although the numbers are too small to
make any definitive statements in this regard.
Ourgrouppreviously reported alterations inglycosylation in
other types of cancers.7,8 The changes in the glycan structures
wehave reported thus far and in this article demonstrate limited
but distinguishable overlap, thus suggesting they are cancer
specific. However, thorough validation of such specificity is
needed and currently being pursued. Another potentially
interesting observation made in the current study is the finding
of decreased fucosylation in esophageal adenocarcinoma
specimens. This is not in agreement with the reported
finding of increased fucosylation in other types of cancers,
such as pancreas and colorectal cancers.14,15 We also faileddiovascular Surgery c Volume 139, Number 5 1219
Structure Trend P-value ROC AUC Sensitivity specificity
Decrease 2.60E-09 0.99 ± 0.01 100 92
Decrease 2.10E-07 0.95 ± 0.03 100 90
Decrease 1.81E-08 0.90 ± 0.04 83 86
Decrease 4.67E-05 0.88 ± 0.05 88 66 
Decrease 4.13E-07 0.87 ± 0.06 77 82 
Increase 6.70E-05 0.86 ± 0.06
88 78 
Increase 1.10E-05 0.84 ± 0.06 66 82 
Decrease 1.96E-08 0.82 ± 0.06
83 64 
Decrease 4.45E-07 0.79 ± 0.08 94 42 
Decrease 1.17E-05 0.79 ± 0.08 89 68 
Decrease 8.43E-06 0.77 ± 0.08
89 62 
Decrease 2.22E-05 0.76 ± 0.07 83 86 
Decrease 1.67E-07 0.76 ± 0.07
89 86 
Decrease 2.49E-06 0.75 ± 0.07 89 58 
Decrease 0.0002 0.74 ± 0.08 78 78 
Decrease 0.007 0.74 ± 0.08 83 66 
FIGURE 3. Area under the curve values from receiver operating characteristic analysis, P values of Wilcoxon rank-sum test, and test sensitivity and spec-
ificity for N-glycans derived from human blood serum of control patients and patients with esophageal adenocarcinoma. Green ¼ mannose;
yellow ¼ galactose; blue ¼ N-acetylglucosamine; red ¼ fucose; purple ¼ N-acetylneuraminic acid. The first 3 rows are the N-glycans that received highly
accurate ROC analysis AUC values (AUC>0.8) and low P values in the Wilcoxon rank-sum test, whereas others are N-glycans that received moderately
accurate ROC analysis AUC values (0.7<AUC<0.8) and low P values in theWilcoxon rank-sum test. AUC,Area under the curve; ROC, receiver operating
characteristic.
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studies have reported altered sialylation in various cancer
types.16,17 Such observations suggest that these findings
may be unique to esophageal adenocarcinoma and that
glycomic profiling is disease specific, thus supporting its
potential use as a diagnostic tool.1220 The Journal of Thoracic and Cardiovascular SurStudy Limitations
There are several limitations to our work. The number of
samples analyzed is small, and further work will be needed
to validate the findings. Ideally, the results obtained in the
current study can serve as a test set, and ‘‘blinded’’ analysis
of further additional specimens will serve to validate ourgery c May 2010
FIGURE 4. Dot-plot of the first 4 structures listed in Figure 3 (sensitivity
100, specificity 96).
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and are currently analyzing additional specimens in an at-
tempt to validate our findings. Other disease states, such asFIGURE 5. Dot-plot analysis of various clini
The Journal of Thoracic and Caresophagitis and other types of tumors, must also be analyzed
and compared. Furthermore, only a prospective, blinded anal-
ysis will determine the ultimate validity and potential clinical
utility of glycomic profiling. Another potential limitation is
the ability to reproduce the results. The repeatability of MS
for glycomic analysis was addressed in a pilot study con-
ducted by the Human Proteome Organisation Human Disease
Glycomics/Proteome Initiative and included 20 different
laboratories, including ours. The study involved comparing
the MS analysis of N-linked glycans of standard samples
acquired in 20 laboratories18 and concluded that in general,
MALDI/time of flight MS of permethylated oligosaccharide
mixtures performed in 6 laboratories yielded good quantita-
tion. The study also revealed the high repeatability and repro-
ducibility ofMS analysis of permethylated glycans. There are
also confounding variables that have the potential to alter any
analysis of blood serum, including comorbid conditions, diet,
age, and gender. Although it is difficult, if not impossible, to
control for all such factors, the patterns observed between
individuals in each of the 4 sample groups were remarkably
consistent, suggesting that the findings were not highly
affected by such factors. We also obtained all samples fromcal stages of esophageal adenocarcinoma.
diovascular Surgery c Volume 139, Number 5 1221
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consumption. In addition, the control group should also be
closely matched to the disease group with regard to age, gen-
der, and so forth. However, we wanted controls to be free of
any possible disease that may confound our results. Given the
typical age and comorbid conditions of patients with esopha-
geal adenocarcinoma, it was exceedingly difficult to find
controls in a similar age group without any comorbid condi-
tions. We also do not have information regarding the proteins
that underwent the detected glycomic changes. This endeavor
will be undertaken once our data have been validated. It
should be noted, however, that the mere identification of
a glycomic ‘‘pattern’’ or ‘‘signature’’ may nonetheless prove
clinically useful even in the absence of the identification of the
specific protein(s).
CONCLUSIONS
We demonstrated the potential of MS-based serum glyco-
mic profiling in the diagnosis of esophageal adenocarcinoma
and its precursor lesions. The data provide some insight into
the mechanisms of altered glycosylation and may thus
indicate structural changes in glycoproteins. Such methodol-
ogies may form the basis for future clinical applications,
such as disease screening or monitoring through the detec-
tion of glycan-specific biomarkers. Further validation and
future prospective studies are needed to confirm the utility
of glycomic profiling.
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Dr A. Pennathur (Pittsburgh, Pa). Dr Hammoud, that was an
excellent presentation and a very interesting study. In your study
you examined the serum samples of 5 patients with BE, 11 patients
with HGD, and 50 patients with esophageal cancer, the majority of
whom had locally advanced or metastatic disease. You identified 26
known glycan structures that were significantly different, and
among these, 8were different in all pairwise comparisons. You con-
cluded that a subset of glycans can be selected as candidate bio-
markers for the differentiation of controls, BE, and esophageal
cancer and that further validation will be necessary. This is an inter-
esting study, and I agree that further validation will definitely be
necessary. One of the difficulties with serum proteomics or profiling
is to standardize the conditions at the time of collection of the sam-
ple.Were these samples obtained in the office or the operating room,
was the patient awake or under anesthesia, and were these samples
handled similarly across the spectrum of all these categories?
Dr Hammoud. They were collected in the clinic. We made sure
that patients were in a fasting state when they came to see us, and
they were all done by the same person in terms of isolating the se-
rum so we could control the protocol.
Dr Pennathur. Excellent. Were these samples from patients
with HGD obtained in patients who had undergone esophagec-
tomy? As you well know, several surgical series have demonstrated
occult cancer in approximately 40% of patients with HGDwho had
undergone esophagectomy. The serum sample from a small sample
size of 11 patients with HGD determined purely by endoscopy may
confound your results.
Dr Hammoud. That is absolutely true. There were 6 patients in
that cohort who underwent surgery and at surgery were docu-
mented and confirmed to have only HGD. The other 5 were endo-
scopic procedures.
Dr Pennathur. Are you planning any longitudinal follow-up in
your patients with BE to determine changes in the profile, and do
we know which proteins are glycosylated?
Dr Hammoud. No, we are not longitudinally following them,
and we have not yet gotten to the point where we’re looking at
the proteins involved.gery c May 2010
Hammoud et al General Thoracic SurgeryDr D. Harpole (Durham, NC). This is fascinating. As a next
step, obviously you could perform MALDI in another set of pa-
tients and see if you come up with the same profile, and you may
or may not. What would be your step in making this a more user-
friendly test? In other words, are you going to try and identify
the proteins through MS/MS and develop a serum enzyme-linked
immunosorbent assay test or something for the glycosylated pro-
teins you have discovered, or do you think this is just exploratory
and you actually want to have a larger patient population and refine
your dataset before you develop a test?
Dr Hammoud. The latter. We definitely need more sample sets.
As you know, even in Pittsburgh and large centers, they only seeThe Journal of Thoracic and Carapproximately 150 of these cases per year. We see approximately
50 to 60 cases per year. So I need several years to collect the spec-
imens and have a large enough pool to refine the data. My ultimate
goal is not really the proteins. I think that’s kind of a Holy Grail,
kind of like looking for the cancer suppressor gene that’s responsi-
ble for something. My ultimate goal is to generate MS profiles, and
if we can identify and correlate a profile that says HGD in a patient
is going to progress to adenocarcinoma, I consider that a clinically
relevant thing to do.
Dr Harpole. A MALDI fingerprint, in other words.
Dr Hammoud. Correct.diovascular Surgery c Volume 139, Number 5 1223
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